Search 

Neurodyn Inc. (neurodyn.ca) is a Canadian biotechnology company using a portfolio approach to identifying, validating and developing natural bioactives into both prescription drugs and natural products for the early treatment of Alzheimer's Disease, Parkinson's Disease and other neurodegernative disorders. 

Memogain® is a patented pro-drug of an existing major Alzheimer's cognition enhancement drug, offering improved side effect profile and increased bioavailability. Initial Phase 1A results have been positive, showing no significant side effects and improved working memory in young and elderly volunteers. Memogain may qualify for a new US FDA accelterated pathway or Eu equivalent.

Cerbella™ is a treatment for early stage Parkinson's disease which has demonstrated in-vivo pre-clinical efficacy in acute models as well as Neurodyn's proprietary chronic model of Parkinson's disease. A product is expected to launch in Canada, USA or other countries in 2015.

NeuroPro® is a professionally-oriented supplement launched in October 2013, designed for neuroprotection and bansed on 5 years of animal model research.

Nerve Pain Treatment (PN34) is a rare first-in-class neuromodulator, being prepared for a topical orphan status nerve paincondition, with clinical trials to begin in 2015.

Progranulin (ND602) is a novel therapeutic demonstrating in-vivo pre-clinical efficacy in ALS, PD< Alzheimer's disease and Spinal Muscular Atrophy. The company is in its third year of collaboration (late stage pre-clinical evaluation) with the Michael J. Fox Foundation.

Neuro Networks Fund is a Venture Philanthropy fund that was established in 213. The fund is looking to make equity investments into companies and projects ranging from $25 for research projects and up to $5 million for early stage companies. The firm will reinvest all returns from these investments back into its fund in an evergreen structure. The firm hopes to begin making its first investments as soon as Q4 214 but is currently very open to discussion and networking with companies in its target sectors. The firm is open to review opportunities from around the globe.

New Leaf Venture Partners is a venture capital company formed in 25 with offices in New York and San Mateo California. The firm currently manages two funds with its most recent fund having closed at $45 million in 27. The firm is looking to make equity investments ranging from $1-$25 million over the lifetime of the investment. The firm looks for companies primarily in the United States and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

The NYU Office of Industrial Liaison (OIL) promotes the commercial development of NYU technologies into products to benefit the public, while providing resources to the University to support its research, education, and patient care missions. NYU OIL also facilitates research collaborations between NYU researchers and industry on projects of mutual interest.

In 2013, NYU launched the Office of Therapeutics Alliances (OTA). OTA is a nimble, "virtual biotech" approach to advance novel therapeutic projects by playing on the strengths of NYU in dissecting disease pathways and those of external, professional capabilities in early stage R&D. OTA identifies NYU projects with potential for addressing unmet needs, delineates the path to therapeutic proof of concept and assembles internal and external resources tailored to each specific project’s needs to maximize the likelihood of successful partnerships with biopharma, new biotech startups or disease foundations. 

O2h has a track record of investing in emerging biotech, small molecule and frontier life science starts-ups

A passion for entrepreneurship and life sciences motivates o2h to participate in syndicated seed stage investments. O2h are ready to support the investments with active or passive support to further the objectives of the company.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).

Orphagen’s focus is small molecule discovery at novel drug targets. We create programs leading to first-in-class drugs. Our goal is to partner these with development stage pharmaceutical companies.

We have been first mover in creating three discovery programs for novel targets, including one program that initiated Phase 1 clinical trials with a strategic partner (JT Pharma) in 2013 for autoimmune disease.

We work with novel drug targets from a very productive target class, the nuclear receptors.

Our work has so far been funded by $15 M in federal grants and partnership revenue. Orphagen is in the process of raising equity funding to accelerate current programs.

Orphagen’s lead internal program is for retinitis pigmentosa, the major form of hereditary blindness. Closely following are antagonists to SF-1, a promising target for treatment of Cushing’s syndrome, a life-threatening endocrine disorder, and two cancers with an endocrine connection: prostate cancer and adrenocortical cancer. New target screening may lead to first-in-class programs for glioblastoma, sickle cell anemia, and cancer immunotherapy.

Pappas Ventures is a Venture Capital company based in Durham North Carolina founded in 1994. The firm manages 4 funds for a total of approximately $35 million in assets under management. The firms is currently investing out of its $1 million 4th fund focused exclusively on the life sciences. The firm looks to provide up to $5 million of preferred equity capital in the initial round and up to $1 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm plans to make 2-3 investments over the next 6-9 months and will consider companies throughout North America.

PATH is an international nonprofit global health organization that was founded in 1977 and is headquartered in Seattle with 12+ employees in more than 3 offices around the world. PATH is one of the largest nonprofit organizations in global health today. PATH works on a wide array of emerging and persistent global health issues in the areas of health technologies maternal health child health reproductive health vaccines and immunization and emerging and epidemic diseases such as HIV malaria and tuberculosis. PATH is best known for developing and adapting technologies such as improved vaccination devices and new tools to prevent cervical cancer to address the health needs of developing countries. It targets health problems evaluates possible solutions and assesses whether they would be useful in finding health solutions.

PBM Capital is a hybrid family office and operating company based in Charlottesville Virginia with an additional office in New York City. The firm is funded and led by the successful life science entrepreneur Paul Manning who started and sold several companies in his career. The firm can make investments ranging from approximately $5 to $1 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity controlling interest in-licensing MBO/LBO growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.